The importance of gallium-68 DOTA-Tyr3-octreotate ( 68 Ga DOTATATE) positron emission tomography/computed tomography (PET/CT) in the imaging of neuroendocrine tumors (NETs) has grown substantially over the past decade and is becoming markedly more common. We present the case of a male with known metastatic NET who underwent 68 Ga DOTATATE PET/CT for restaging, incidentally revealing intense uptake of the prostate with a maximum standard uptake value of 17.4. Due to the patient's medical history, this finding was concerning for neuroendocrine prostate cancer. However, core biopsies of the prostate were negative for malignancy and positive for chronic inflammation. Chronic prostatitis is a very common condition in adult males and is often asymptomatic. Inflammatory conditions, including prostatitis, are important causes of false-positive findings on 68 Ga DOTATATE PET/CT and should be considered as part of the differential diagnosis, even in an asymptomatic patient.
INTRODUCTION
Gallium-68 DOTA-Tyr3-octreotate ( 68 Ga DOTATATE) is a radiolabeled somatostatin receptor analog with rising use in positron emission tomography/computed tomography (PET/CT), especially in the imaging of neuroendocrine tumors (NETs). With a sensitivity of 95.1%, many would argue that 68 Ga DOTATATE PET/CT is the new gold standard in NET imaging. [1] We present a case of a unique false positive on a 68 Ga DOTATATE PET/CT study in which the prostate showed diffuse, intense avidity. There was initially concern for neuroendocrine prostate cancer (NEPC), but on biopsy, the uptake was found to be due to asymptomatic inflammatory prostatitis (AIP).
CASE REPORT
A 60-year-old male with metastatic NET presented after a surveillance CT showed progression of his disease. He was initially diagnosed with NET 3 years earlier, after presenting for a small bowel obstruction. Surgical pathology at the time showed a well-differentiated, low-grade NET originating in the small bowel with a Ki-67 of 2%. Imaging was suggestive of metastatic disease with multiple liver lesions and intra-abdominal and peripancreatic lymph nodes, of which one liver lesion and one lymph node were pathologically confirmed to be NET. He was treated with lanreotide, a somatostatin analog in the interim. 
Case Report
The patient was followed with surveillance CT scans every 4-6 months. His most recent surveillance CT showed increased size of the major metastatic liver lesion and increased intra-abdominal lymphadenopathy, prompting this presentation. At this time, he had no urinary, bowel, sexual, or pelvic pain complaints that would suggest prostatic disease and was otherwise asymptomatic. Eight months before the current presentation, he was found to have an elevated prostate-specific antigen (PSA) of 4.3 ng/mL, though his PSA had since normalized to 1.42 ng/mL. A 68 Ga DOTATATE PET/CT was performed to further characterize his disease and assess his candidacy for peptide receptor radionuclide therapy. 68 Ga DOTATATE PET/CT showed radiotracer avid metastatic disease of the liver, mesentery, and peripancreatic lymph nodes, with a maximum standard uptake value (SUVmax) of 23.9, indicating that the previously identified disease progression was somatostatin receptor positive ( Figure 1 , Arrow: Metastasis to Liver). Surprisingly, the scan also showed focal, intense uptake of the prostate with an SUVmax of 17.4 [ Figure 2 , arrows]. With concern that this could represent NEPC, the patient underwent ultrasound-guided biopsy of the prostate. Twelve core biopsies showed multiple foci of acute and chronic inflammation, no organisms, and no concern for neoplasm. The patient has since begun 177 Lu-DOTATATE therapy for his disease and is doing well 8 months later.
DISCUSSION
Among clinicians, NEPC is of increasing interest. NEPC is a rare group of castrate-resistant cancers with neuroendocrine genetic alterations, most commonly small cell carcinoma. As opposed to prostate adenocarcinoma, NEPC is not driven by testosterone stimulation, rendering NEPC impervious to the standard prostate cancer therapies that target the androgen system. NEPC is much more aggressive than prostate adenocarcinoma, those diagnosed with de novo NEPC have a dismal median survival of only 10 months and 5-year overall survival of 12.6%, compared to a 5-year overall survival that approaches 100% for localized prostate adenocarcinoma. [2] [3] [4] Thus, it is of great importance to identify NEPC to initiate the proper treatment algorithms and provide an accurate prognosis for the patient.
Prostatitis is a common condition, as it is estimated that 50% of males will experience symptoms of prostatitis at some point in their lives. The National Institutes of Health divides prostatitis into four categories: acute bacterial prostatitis, chronic bacterial prostatitis, chronic prostatitis/chronic pelvic pain syndrome, and AIP. [5] AIP is the least understood of these subtypes, although it appears to be relatively common. As the name implies, these patients have no symptoms of prostatitis and are often diagnosed incidentally, usually after an elevated PSA leads to a biopsy for the workup for prostate cancer, or when elevated semen leukocyte levels are discovered during an infertility workup. It is difficult to determine the exact prevalence of AIP since it often goes undetected, although it has been estimated that anywhere between 6.0% and 32.2% of males could show evidence of AIP at a given time. [6] Our patient is a typical presentation of AIP, as it was not discovered until there was a concern for NEPC.
Active inflammation is known to cause false-positive DOTATATE uptake, which is thought to be due to the high concentration of somatostatin receptors expressed by white blood cells. [7] The American College of Radiology guidelines on 68 Ga DOTATATE in NET reports that prostatitis causes physiologic uptake of the radiotracer. [8] However, actual evidence of this in the literature is scarce. Furthermore, studies have shown that prostate uptake is usually in the range of SUV 3.5-7. [9, 10] Due to the magnitude of the uptake above this threshold with an SUVmax of 17.4, there was a concern initially that this patient had neuroendocrine variant of prostate cancer.
This case demonstrates important teaching points for the increasing number of nuclear medicine physicians who are using 68 Ga DOTATATE PET/CT. In the event of an unexpected positive finding of prostate uptake, it is critical to know that prostatitis, regardless of symptomatology, can cause false-positive uptake. Thus, the next step in the management should be to reexamine the patient with a particular focus on genitourinary signs and symptoms. The positive uptake of the prostate is much more likely to be due to prostatitis than NEPC simply because of the relative prevalence of the two diseases. However, in this patient with a history of NET, evidence of progression of disease, and radiotracer uptake that was more avid than what would be expected in prostatitis, further workup was deemed appropriate to confirm the extent of his disease before escalating therapy.
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